Who was studied, and how
Two numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 2 other studies
433people with obesity, in this paper
The trial randomly assignedassigned by chance
metformin
control (placebo or no treatment)
Probably lowered serum CRP levels−1.23
randomisedThe trial randomly assignedassigned by chance
metformin treatment beyond 6 months
metformin treatment less than 6 months
Reported lower serum CRP levels, no range given−1.47
randomisedthe abstract, start to end
… after metformin treatment (WMD = -1.23mg/L, 95%CI: -1.65 to -0.81, I2 …
… treated beyond 6 months (WMD≥6months = -1.47mg/L vs.
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Serum CRP levelsmetformin vs control (placebo or no treatment)
−1.23−1.65 to −0.81
Serum CRP levelsmetformin treatment beyond 6 months vs metformin treatment less than 6 months
−1.47
MetforminInflammation & biomarkers
Metformin × inflammation & biomarkershelps?one trial
unlikelylikely
0.50not counted
← favours comparatorfavours treatment →
1 / 7